eXoZymes Inc Financials
This page shows eXoZymes Inc (EXOZ) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
eXoZymes Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, eXoZymes Inc generates $1.45 in operating cash flow (-$8.5M OCF vs -$5.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
eXoZymes Inc's EBITDA was -$5.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 254.2% from the prior year.
eXoZymes Inc generated -$8.9M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 505.8% from the prior year.
eXoZymes Inc reported -$5.9M in net income in fiscal year 2024. This represents a decrease of 187.5% from the prior year.
eXoZymes Inc earned $-0.89 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 169.7% from the prior year.
eXoZymes Inc held $9.7M in cash against $0 in long-term debt as of fiscal year 2024.
eXoZymes Inc had 8M shares outstanding in fiscal year 2024. This represents an increase of 33.9% from the prior year.
eXoZymes Inc invested $1.9M in research and development in fiscal year 2024. This represents an increase of 254.3% from the prior year.
eXoZymes Inc invested $396K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 37.3% from the prior year.
EXOZ Income Statement
| Metric | Q3'25 | Q3'25 | Q3'25 | Q3'24 | Q3'24 | Q3'24 | Q3'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $1.2M+51.5% | $803K+39.6% | $575K | N/A | $723K+204.8% | $237K-14.5% | $278K | N/A |
| SG&A Expenses | $1.3M-25.2% | $1.7M+26.8% | $1.4M | N/A | $888K-18.6% | $1.1M+49.3% | $731K | N/A |
| Operating Income | -$2.5M+1.0% | -$2.5M-30.6% | -$2.0M | N/A | -$1.6M-21.3% | -$1.3M-31.7% | -$1.0M | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | $45K | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | $2K | N/A | N/A |
| Net Income | -$2.3M+3.1% | -$2.4M-27.1% | -$1.9M | N/A | -$1.7M-21.7% | -$1.4M-34.9% | -$1.0M | N/A |
| EPS (Diluted) | $-0.27+3.6% | $-0.28-27.3% | $-0.22 | N/A | $-0.27-22.7% | $-0.22-37.5% | $-0.16 | N/A |
EXOZ Balance Sheet
| Metric | Q3'25 | Q3'25 | Q3'25 | Q3'24 | Q3'24 | Q3'24 | Q3'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.7M-20.2% | $9.7M-16.0% | $11.5M-11.6% | $13.0M+266.1% | $3.6M | N/A | N/A | $3.6M |
| Current Assets | $5.6M-25.6% | $7.5M-20.0% | $9.4M-13.0% | $10.8M+660.6% | $1.4M | N/A | N/A | $1.2M |
| Cash & Equivalents | $5.1M-27.0% | $7.0M-17.9% | $8.5M-12.4% | $9.7M+4054.7% | $234K+47.8% | $158K+39.1% | $114K+71.0% | $67K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $2.3M-4.0% | $2.4M-7.7% | $2.6M+1.2% | $2.6M-63.5% | $7.2M | N/A | N/A | $3.9M |
| Current Liabilities | $1.2M+1.8% | $1.2M-15.7% | $1.4M+8.3% | $1.3M-77.0% | $5.8M | N/A | N/A | $2.4M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $5.4M-25.7% | $7.2M-18.5% | $8.9M-14.8% | $10.4M+389.4% | -$3.6M-59.2% | -$2.3M-81.0% | -$1.2M-225.2% | -$384K |
| Retained Earnings | -$18.4M-14.1% | -$16.2M-17.1% | -$13.8M-15.5% | -$11.9M-18.2% | -$10.1M | N/A | N/A | -$6.1M |
EXOZ Cash Flow Statement
| Metric | Q3'25 | Q3'25 | Q3'25 | Q3'24 | Q3'24 | Q3'24 | Q3'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.9M-20.7% | -$1.5M-35.7% | -$1.1M+80.1% | -$5.7M-954.0% | -$542K+78.7% | -$2.5M-1002.5% | $281K+135.9% | -$783K |
| Capital Expenditures | $13K-73.7% | $51K+62.9% | $31K-85.2% | $210K | $0-100.0% | $37K-75.0% | $149K+35.6% | $110K |
| Free Cash Flow | -$1.9M-17.7% | -$1.6M-36.4% | -$1.2M+80.3% | -$5.9M-992.8% | -$542K+79.0% | -$2.6M-2045.0% | $132K+114.8% | -$893K |
| Investing Cash Flow | -$13K+56.9% | -$31K+0.6% | -$31K+85.2% | -$210K-781.9% | $31K+182.9% | -$37K+73.9% | -$142K-29.8% | -$110K |
| Financing Cash Flow | N/A | N/A | -$43K-100.3% | $15.4M+2526.9% | $586K-77.6% | $2.6M+2962.6% | -$92K-118.9% | $485K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
EXOZ Financial Ratios
| Metric | Q3'25 | Q3'25 | Q3'25 | Q3'24 | Q3'24 | Q3'24 | Q3'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -29.6%-5.2pp | -24.4%-8.3pp | -16.1% | N/A | -46.5% | N/A | N/A | N/A |
| Current Ratio | 4.53-1.7 | 6.19-0.3 | 6.52-1.6 | 8.12+7.9 | 0.25 | N/A | N/A | 0.50 |
| Debt-to-Equity | 0.44+0.1 | 0.34+0.0 | 0.30+0.0 | 0.25+2.2 | -1.99 | N/A | N/A | -10.26 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is eXoZymes Inc profitable?
No, eXoZymes Inc (EXOZ) reported a net income of -$5.9M in fiscal year 2024.
What is eXoZymes Inc's earnings per share (EPS)?
eXoZymes Inc (EXOZ) reported diluted earnings per share of $-0.89 for fiscal year 2024. This represents a -169.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is eXoZymes Inc's EBITDA?
eXoZymes Inc (EXOZ) had EBITDA of -$5.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is eXoZymes Inc's free cash flow?
eXoZymes Inc (EXOZ) generated -$8.9M in free cash flow during fiscal year 2024. This represents a -505.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is eXoZymes Inc's operating cash flow?
eXoZymes Inc (EXOZ) generated -$8.5M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are eXoZymes Inc's total assets?
eXoZymes Inc (EXOZ) had $13.0M in total assets as of fiscal year 2024, including both current and long-term assets.
What are eXoZymes Inc's capital expenditures?
eXoZymes Inc (EXOZ) invested $396K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does eXoZymes Inc spend on research and development?
eXoZymes Inc (EXOZ) invested $1.9M in research and development during fiscal year 2024.
How many shares does eXoZymes Inc have outstanding?
eXoZymes Inc (EXOZ) had 8M shares outstanding as of fiscal year 2024.
What is eXoZymes Inc's current ratio?
eXoZymes Inc (EXOZ) had a current ratio of 8.12 as of fiscal year 2024, which is generally considered healthy.
What is eXoZymes Inc's debt-to-equity ratio?
eXoZymes Inc (EXOZ) had a debt-to-equity ratio of 0.25 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is eXoZymes Inc's return on assets (ROA)?
eXoZymes Inc (EXOZ) had a return on assets of -45.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is eXoZymes Inc's cash runway?
Based on fiscal year 2024 data, eXoZymes Inc (EXOZ) had $9.7M in cash against an annual operating cash burn of $8.5M. This gives an estimated cash runway of approximately 14 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is eXoZymes Inc's Piotroski F-Score?
eXoZymes Inc (EXOZ) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are eXoZymes Inc's earnings high quality?
eXoZymes Inc (EXOZ) has an earnings quality ratio of 1.45x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.